FDA approves Dr Reddy’s NDA for migraine drug

Dr Reddy’s Laboratories has said the companys NDA (new drug application) Elyxyb ((celecoxib oral solution 25 mg/mL) has been approved by the US Food and Drug Administration (FDA).

Elyxyb (previously known as DFN-15), which is indicated for the acute treatment of migraine with or without aura in adults, is the latest product emerging from Dr Reddy’s portfolio of successful acute migraine treatments.

The company is working to commercialise this product through partners, a press release from the city-based drug maker said recently.

“We are excited about the approval of Elyxyb. It reaffirms our commitment to innovation and to develop meaningfully differentiated products that address significant unmet needs of patients and physicians, leading to better health outcomes,” Erez Israeli, CEO, Dr Reddy’s Laboratories, said.

According to Anil Namboodiripad, Sr Vice President – Proprietary Products Group, Dr Reddy’s, in pivotal studies, Elyxyb demonstrated a rapid onset of action which is critically important to patients suffering from acute migraine attacks.

The results from the studies established the efficacy of celecoxib in the treatment of migraine with very few adverse events, Namboodiripad added.

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.